With only a partial article posted it's impossible to see what actual conclusions they've come too. However there's another study that was done with Verteporfin and maraviroc. Verteporfin downregulates CCL5. This study shows that Vertepofin has good effect and even better effect when combined with maraviroc. We know that maraviroc has around an 84% CCR5 occupancy rate vs. 100% for leronlimab so it will not have the higher effect that leronlimab has with CCR5. Also CCL5 is not the only CCR5 ligand involved in cancer that both maraviroc and leronlimab control. But CCL5 also binds CCR1, CCR3 and CCR4 (although to a lesser extent then CCR5) so the downregulation of CCL5 by Vertepofin would also control those interactions to some extent. This could lead to immunosuppression with the use of Vertepofin. This immunosuppression may be worthwhile shorter term in the case of something as deadly as cancer but may not be as worthwhile in any disease where it's use would be long term.

Quote:

---

Targeting a positive regulatory loop in the tumor-macrophage interaction impairs the progression of clear cell renal cell carcinoma
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937678/

---